PCD Pharma Franchise Opportunities in Jammu and Kashmir with Daksh Diabetes and Cardiac Care
Recent data from the ICMR-INDIAB study reveals that Jammu and Kashmir is facing an alarming health crisis, with diabetes and hypertension reaching epidemic proportions across the Union Territory. According to the landmark ICMR-INDIAB national study, the overall prevalence of diabetes in Jammu stands at a staggering 18.9%, with an alarming 26.5% in urban areas and 14.5% in rural areas. This means nearly one in five adults in Jammu is living with diabetes, a figure almost double the national average.
The burden of prediabetes is equally concerning, affecting 10.8% of the population—with urban areas showing 13.4% and rural areas 9.3% . Alarmingly, 40% of individuals had undiagnosed diabetes, highlighting a massive gap in screening and early detection. This means many are unaware of their condition until complications develop. Studies across Kashmir show that around 19% of adults in the Union Territory live with diabetes, placing the region among the highest in North India.
The burden of hypertension adds another layer of concern. According to NFHS-5, only 36% of women and 31% of men in Jammu and Kashmir have normal blood pressure, with 57% of the population falling in the pre-hypertensive category. This means over half the population is at immediate risk of developing full-blown hypertension. The overall prevalence of hypertension in Jammu is 27.1%. A study among the tribal Gujjar and Bakarwal populations found an even higher hypertension prevalence of 41.4%.
The solution lies in integrated diabetic and cardiac care, as diabetes is not just about blood sugar it is a chronic metabolic condition that progressively damages blood vessels, leading to blockages, heart attacks, strokes, and nerve damage (neuropathy) that affects heart rate regulation. Adults with diabetes are two to four times more likely to develop heart failure, making early intervention critical. At Daksh Diabetic & Cardiac Care, we provide affordable, quality assured medications for both diabetes management and heart protection, including SGLT2 inhibitors like DYFOZIN (Dapagliflozin) for heart and kidney protection, statins like ROSADAC (Rosuvastatin) for cholesterol control, ARBs like DYTEI (Telmisartan) for blood pressure management, and metformin like GLYCODIP SR for blood sugar control. With WHO-GMP certified quality and competitive pricing, Daksh empowers J&K families through regular screening, medication adherence, lifestyle modifications, and early detection ensuring thousands become success stories of integrated care and better health outcomes.
How Daksh is making a Difference in Jammu and Kashmir
1. Affordable, Quality-Assured Medications
Daksh Diabetic & Cardiac Care was established with a clear mission: to make quality pharmaceutical products available at affordable costs. As part of the Daksh Group of Companies which has over two decades of experience in the pharmaceutical industry the company brings credibility and trust to the diabetic and cardiac care segment.
What this means for J&K patients:
- Access to WHO-GMP certified medications
- Lower out-of-pocket expenses for lifelong treatments
- No compromise on quality despite affordable pricing
2. Complete Cardiac Care Portfolio
Daksh offers a comprehensive range of cardiac care products that address the full spectrum of heart health needs:
| Product Category | Daksh Offerings | Purpose |
| ACE Inhibitors | DORAPIL (Ramipril) | Blood pressure control, heart failure treatment |
| ARBs | CARDIOVIL (Losartan), DYTEI (Telmisartan), OLMIDIP (Olmesartan) | Hypertension management |
| Beta-Blockers | CARDIOVIL (Carvedilol), METODIP (Metoprolol), NEBIDAC (Nebivolol) | Heart rate control, heart failure |
| Calcium Channel Blockers | DUPIN (Amlodipine), CLINITAC (Cilnidipine) | Blood pressure, angina |
| Diuretics | TORDAC (Torsemide), FRUSIDIP | Fluid management in heart failure |
| Lipid Management | ROSADAC (Rosuvastatin), ATRODAC (Atorvastatin) | Cholesterol control |
3. Complete Diabetic Care Portfolio
For diabetes management, Daksh provides modern therapeutic options including:
| Product Category | Daksh Offerings |
| SGLT2 Inhibitors | DYFOZIN (Dapagliflozin) – the modern heart-protective diabetes drug |
| DPP-4 Inhibitors | TENADAC (Teneligliptin), SITADAC (Sitagliptin), VILDADAC (Vildagliptin) |
| Sulfonylureas | GLIMIDAC (Glimepiride) |
| Biguanides | GLYCODIP SR (Metformin) |
| Combination Therapies | DYFOZIN M, GLIMIDAC MV (triple combination) |
4. Focus on Preventive Care
Daksh’s product portfolio includes nutritional supplements and preventive therapies that help patients maintain better health and avoid complications:
- Liver tonics for medication-induced liver protection
- Calcium supplements for bone health (critical for diabetic patients)
- Vitamin complexes for overall metabolic support
5. Supporting Healthcare Providers across Jammu and Kashmir
Daksh works with hospitals, clinics, and pharmacies across Jammu and Kashmir to ensure that quality medications reach every corner of the Union Territory. Through its PCD pharma franchise model, local entrepreneurs can partner with Daksh to serve their communities while building sustainable businesses.
With the region’s high disease burden and growing healthcare sector, there is immense potential to build a meaningful healthcare business while serving your community. Popular locations for PCD franchise opportunities include Srinagar, Jammu, Anantnag, Baramulla, Udhampur, Kathua, and Rajouri.
Conclusion
The diabetes and heart disease epidemic in Jammu and Kashmir is not just a statistic it is a reality affecting hundreds of thousands of families. With the Union Territory recording an 18.9% diabetes prevalence, a 27.1% hypertension prevalence, and 40% of diabetics undiagnosed, the burden is immense and growing. But there is hope. With the right medications, proper awareness, and accessible healthcare, patients can live long, healthy, and fulfilling lives.
Daksh Diabetic & Cardiac Care is committed to being part of this solution providing affordable, quality-assured pharmaceutical products that align with the latest clinical guidelines.
Contact Daksh Diabetic and Cardiac
| Contact Method | Details |
| Office Address | Plot 249, Daksh House, Industrial Area Phase 2, Panchkula – 134109, Haryana, India |
| Phone | 📞 +91 93565 60523 📞 +91 78886 02869 |
| enquirypurchase.daksh@gmail.com | |
| Contact us | https://diabetes-cardiac.com/contact-us/ |